FDA To Disclose More On Paragraph IV ANDA Filings
This article was originally published in The Tan Sheet
Executive Summary
FDA's posting of dates when Paragraph IV applications are filed will allow generic firms to assess whether they are eligible for the 180-day exclusivity and improve planning of their filings
You may also be interested in...
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer
Zyrtec-D Paragraph IV Application Submitted To FDA
A generic version of Pfizer's Zyrtec-D 12 Hour is among the Paragraph IV abbreviated new drug applications submitted to FDA early this summer